Podcasts about abstracts

In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovations, and Techniques (JVS-CIT). Editorials and Abstracts are read by Authors as well as members of the SVS Social Media Ambassadors.    Guests: Juliet Blakeslee-Carter, MD (@AWBeckMD) The value and structure of writing a vascular surgery case report: A student's guide   Neha Gupta (@nehaha00) We don't know what we don't know, until we do Colonic ischemia and the role of inferior mesenteric artery reimplantation after abdominal aortic aneurysm repair Abdominal aortic aneurysm classification based on dynamic intraluminal thrombus analysis during cardiac cycle Quantitative intra-arterial fluorescence angiography for direct monitoring of peripheral revascularization effects   Ben Li, MD (@ben_li123) An introduction to the journal review and editorial process   Hosts: John Culhane (@JohnCulhaneMD)  Follow us @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.   *Gore is a financial sponsor of this podcast, which has been independently developed by the presenters and does not constitute medical advice from Gore. Always consult the Instructions for Use (IFU) prior to using any medical device.    

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Episode 54: June 21, 2025 Nigel Sade and Echo discuss juggling personal art and commissions - the artist's version of work/life balance. About Nigel Sade “Nigel Sade was born on a bright and sunny day nearly to some, and exactly to others, 40 years after D-day. Some consider this meaningful whilst the rest laugh at those people, but I digress. He was raised in hell ... or rather Ohio but I don't want to split hairs. In a smallish county called Portage. As a child he could be found drawing on any surface he could make a mark on, and with all the moving security deposits were more like donations. In School this A.D.H.D. Toth wannabe (but with hands) was considered a bit strange by his peers, ... a malady that never left him as it turned out. As a teenager he was a rebellious youth, A Technicolored street Freak, delving into every aspect of art, from Drawing to painting to Music to Religion to Science to Philosophy in general. Then there were the dark times ... the marriage! When his soul was crushed by evil and doubt. He Dreamt of being an artist but that was not a real job ... how could you feed a family with that pipe dream? However, In just 6 and a half long agonizing years it was over. On the Up side His torment was not without reward; He now has 2 lovely Spawn with which to explore life. Shortly after his divorce Nigel graduated college with a degree in Philosophy. So Armed with his freedom, his offspring, and an amazing ability to argue points that even he may not believe, he set out on the high seas of art! This was a joyous thing! There was much weirdness, art, travel, debauchery and Success. Stories were made and told, and now he Currently travel the amber waves of grain, questioning whatever reality he is presented with, chewing that up and spitting it out in the form of art. Then Nigel shows that art to the hapless masses in hopes that it moves them as much at it moved him to create it. Nigel's art in form is Symbolism (Much like Surrealism), represented in either a realism or Abstracts, and in function it explores basic ideas we hold, mostly it does so by exploring questions of Reality, Love, Thought and plain old strangeness. Nigel's belief is that art should spur conversation, not just match ones curtains. Now you may ask, "What does all this have to do with piracy?" Well, he was always a grungy, bandana wearin' freak. His family was and is highly Piratical What with their last name Rogers all the family businesses are Jolly Roger this and Jolly Roger that ... Not to mention their propensity for Rum. So with his families' nautical background and the new Pirate craze, the public proclaimed him a pirate, and a pirate he was. Yet, having always loved pirates, one can say Nigel got peanut butter in his chocolate!” Nigels's LinkTree: https://linktr.ee/NigelSade Echo Chernik Links: Website: https://www.EchoChernik.com Illustration: https://www.echo-x.com Facebook: https://www.facebook.com/echoxartist Instagram: https://www.instagram.com/echochernik Patreon: https://www.patreon.com/thexcaliberproject Kickstarter: https://www.kickstarter.com/profile/echox/created

The emergence of foundation models has sparked interest in applications to single-cell biology, but when tested in zero-shot settings, they underperform compared to simpler methods. Alex Lu shares insights on why more research on AI models is needed in biological applications.Show notes

In this episode of Abstracts, Microsoft senior researchers Megan Stanley and Wessel Bruinsma join host Amber Tingle to discuss their groundbreaking work on environmental forecasting. Their new Nature publication, "A Foundation Model for the Earth System," features Aurora, an AI model that redefines weather prediction and extends its capabilities to other environmental domains such as tropical cyclones and ocean wave forecasting.Read the paper: A Foundation Model for the Earth System

Silicon has long borne the burden of heat transfer in electronics, but in a post-Moore's Law world, researchers like Hongxia Hao and Bing Lv are using AI to discover and design next-generation materials that exceed the limits of silicon's thermal conductivity.Read the paper

Presented by the ASC Research and Current Concepts Committee  Vicki Jo, MD, Chair & Amy Ly, MD, Vice Chair Dr. Esma Ersoy interviewed Dr. Caddie Laberiano Fernandez, the winner of the Quality Improvement in Cytology Award. This interview dives into the steps that led to this award-winning platform. Platform 12 Standardizing Pre-analytic Factors in Cytology Specimens for ICC Evaluation and Their Assessment Using Image Analysis Caddie Laberiano Fernandez, MD MD Anderson Cancer Center Houston, Texas Esma Ersoy, MD ASC Research and Current Concepts Committee, Member University of Connecticut Health Farmington, Connecticut Call for Abstracts for Platform and Poster Presentations DEADLINE TO SUBMIT ABSTRACTS - May 1, 2025  Click here  [cytopathology.org]to submit.

New AI models aren't just changing the world of research; they're also poised to impact society. Xing Xie talks about Societal AI, a white paper that explores the changing landscape with an eye to future research and improved communication across disciplines.Read the paper

Presented by the ASC Research and Current Concepts Committee  Vicki Jo, MD, Chair & Amy Ly, MD, Vice Chair Dr. Cathy Bammert interviewed Dr. Lakshmi Harinath, the Geno Saccomanno, MD, New Frontiers in Cytology Award recipient. This interview explores the steps that led to the development of this award-winning platform. Platform 8 Analysis of Sensitivity of High-Grade Squamous Intraepithelial Lesion (HSIL) Pap Diagnosis and Interobserver Variability with Hologic Genius Digital Diagnostics Lakshmi Harinath, MD, MPH University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Catherine E. Bammert, PhD, CT, MBASCP, CTIAC ASC Research and Current Concept Committee, Member UT MD Anderson Cancer Center Houston, Texas  Call for Abstracts for Platform and Poster Presentations DEADLINE TO SUBMIT ABSTRACTS - May 1, 2025  Click here to submit.

In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovations, and Techniques (JVS-CIT). Editorials and Abstracts are read by Authors as well as members of the SVS Social Media Ambassadors.   Guests: Antonio L. Solano, MD (@solanotono) Rotational flap versus long plantar flap for transmetatarsal amputation closure following revascularization   Lucerne milestone approach for benchmarking and education: Towards ultra-low dose endovascular aortic repair   The use of stent grafts for management of junctional vascular injuries: Is this accepted practice?   Hosts: John Culhane (@JohnCulhaneMD)     Follow us @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

Presented by the ASC Research and Current Concepts Committee  Vicki Jo, MD, Chair & Amy Ly, MD, Vice Chair Dr. Danielle Elliott Range interviewed Dr. Nikka Khorsandi, the Excellence in Diversity Equity and Inclusion Research Award recipient. This interview explores the steps that led to the development of this award-winning poster. Poster 22 Anal High-Risk HPV Genotype Prevalence: Unmasking Racial, Gender, and HIV-Related Disparities Nikka Khorsandi, MD, MPH University of California San Francisco, California Danielle Elliott Range, MD Member, ASC Research and Current Concept Committee Duke University Durham, North Carolina Call for Abstracts for Platform and Poster Presentations DEADLINE TO SUBMIT ABSTRACTS - May 1, 2025  Click here to submit.

This isn't reform, it reimagination.  Season 10 begins with a call for radical, anti-racist visions for social work. In this episode, we launch a call for abstracts for the upcoming British Journal of Social Work special issue:  "Reimagining Anti-Racist Social Work - Rooted in Care, Resistance and Solidarity" led by the Anti-Racist Movement. We explore: The purpose and vision of the special issue Who we want to hear from (spoiler: it's not just academics) How to submit your abstract Deadline: Friday 9th May 2025 Submission details, just click: https://academic.oup.com/bjsw/pages/social-work-special-issue-2026. Join us as we kick off a new season rooted in justice, imagination, and action.

Send us a textDuring the Society of Interventional Radiology (SIR) 2025 Annual Scientific Meeting, visit the SIR Today website each day for session previews and recaps, leadership and author interviews, award-winner inspirations, and much more. Tune in to these audio updates each morning for the day's programming highlights, the day's new content coming from SIR Today, and audio clips from article interviews.In the Monday, March 31 edition:Audio clips of interviews with lead presenters of the four Abstracts of the YearCategorical coursesFireside ChatsThe Women in IR InspIRed Lecture and LuncheonFeatured abstracts covered in today's new SIR Today contentSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Presented by the ASC Research and Current Concepts Committee  Vicki Jo, MD, Chair & Amy Ly, MD, Vice Chair Dr. Jonathan Marotti interviewed Ms. Joanna Danczuk, the Innovative Cytologist Practice Award winner. This interview delves into the steps that led to this award-winning platform. Platform 10 Improving the Efficiency of Rapid Onsite Evaluation Utilizing Artificial Intelligence Joanna Danczuk, CT(ASCP) ASP Health Northbrook, Illinois Jonathan Marotti, MD Member, ASC Research and Current Concept Committee Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire Call for Abstracts for Platform and Poster Presentations DEADLINE TO SUBMIT ABSTRACTS - May 1, 2025  Click here  [cytopathology.org]to submit.

Howdy! We are very excited to be back for this special episode! This time we welcome Marios Hedary the owner/operator of Byblos Mediterranean Restaurant. Marios shares his story with us and how he and his restaurant contribute to the art scene in the DFW area.  Jeff will have several pieces of new work on display at the Byblos restaurant during the festival that runs from April 10-13 2025. More info below!! Come for the art, stay for the eggplant! https://wengerabstracts.com/ https://www.byblostx.com/

Join us as we discuss the top quality improvement abstracts from the PCICS 2024 Annual Conference with guests Andy Shin, MD (Lucile Packard Children's Hospital / Stanford University), Melissa Winder, CPNP-AC (Primary Children's Hospital / University of Utah), and Kimberly DiMaria DNP, CPNP-AC (C.S. Mott Children's Hospital / University of Michigan). We cover topics from decreasing mortality rates using a rapid, real-time review process; a multi-centered quality initiative addressing postoperative chylothorax, and improvements in feeding and sedation outcomes through the use of nasotracheal intubation. These abstracts exemplify some of the best quality improvement work presented this year. Hosts: Rambod Amirnovin, MD (Elevance Health; Miller Children's Hospital); Jennifer Gauntt, MD (Nationwide Children's / Ohio State University SOM) Editor: Rambod Amirnovin, MD (Elevance Health; Miller Children's Hospital) Producer: Deanna Tzanetos, MD (University of Louisville/Norton Children's Hospital)

In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovations, and Techniques (JVS-CIT). Editorials and Abstracts are read by Authors as well as members of the SVS Social Media Ambassadors.   Guests: Kelsey Schmittling, Medical Student (@kelseyum2plus) “What can go wrong during thoracic endovascular aortic repair for type B aortic dissection” Development and feasibility testing of a new device for home-based leg heat therapy in patients with lower extremity peripheral artery disease  Radiation-induced injury in endovascular surgery: How long is too long?   Hosts: John Culhane (@JohnCulhaneMD) Nishi Vootukuru (@Nishi_Vootukuru)   Follow us @audiblebleeding  Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

In this episode, podcast cohost Dr. Ashwin Parihar and guest Dr. Jessica Porembka, chair of the RSNA education exhibit awards committee, highlight several standout educational and scientific presentations at RSNA 2024 and discuss larger trends in education and research abstracts at the annual meeting. Call for Abstracts at RSNA 2025 is now open for submissions and closes May 7, 2025 (noon Central Time). Call for Abstracts at RSNA 2025 Abstract Submission | RSNA 2024 RSNA Annual Meeting Awardees DB24_Award_Winners_Thursday_FIN.indd RSNA Involvement Opportunities Volunteer and involvement opportunities | RSNA

In episode 224 of America Adapts we're diving into climate change and human mobility—how rising seas, extreme weather, and disasters are forcing communities to relocate and what that means for policy and planning. Joining the podcast is Dr. Eric Chu, who's helping lead a new webinar series (where America Adapts was the moderator) on this topic with CCST (California Council on Science and Technology), the UC Disaster Resilience Network, and the UC Berkeley Center for Security in Politics. We'll talk about how cities can prepare for climate-driven displacement, how researchers can better engage with policymakers, and what lessons we can take from California's leadership in adaptation.  Eric's been involved in some major climate convenings, including discussions on wildfire smoke and policy action at the university level. There's a lot to unpack! Battelle's ICR25 ICR25 brings together the world's brightest minds to solve the resilience challenge. This year's theme, “Partner, Accelerate, Launch,” highlights the critical need for innovative solutions to reach commercialization and impact resilience. Submit an abstract here:  Abstracts  https://www.battelle.org/conferences/icr  Register here: https://www.battelle.org/conferences/icr/technical-program-registration   Check out the America Adapts Media Kit here! Subscribe to the America Adapts newsletter here. Donate to America Adapts Listen to America Adapts on your favorite app here!   Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Links in this episode: https://ccst.us/register-climate-change-and-human-mobility-briefing-series/ https://www.youtube.com/watch?v=NzT8noY0IVM UC Disaster Resilience Network UC Berkeley Center for Security in Politics https://ccst.us/people/staff/eric-chu/   Doug Parsons and Speaking Opportunities: If you are interested in having Doug speak at corporate and conference events, sharing his unique, expert perspective on adaptation in an entertaining and informative way, more information can be found here! Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Donate to America Adapts   Follow on Apple Podcasts Follow on Android Now on Spotify! List of Previous Guests on America Adapts Follow/listen to podcast on Apple Podcasts. Donate to America Adapts, we are now a tax deductible charitable organization! Federal Reserve Bank of San Francisco Strategies to Address Climate Change Risk in Low- and Moderate-income Communities - Volume 14, Issue 1 https://www.frbsf.org/community-development/publications/community-development-investment-review/2019/october/strategies-to-address-climate-change-low-moderate-income-communities/   Podcasts in the Classroom – Discussion guides now available for the latest episode of America Adapts. These guides can be used by educators at all levels. Check them out here! The 10 Best Sustainability Podcasts for Environmental Business Leadershttps://us.anteagroup.com/news-events/blog/10-best-sustainability-podcasts-environmental-business-leaders Join the climate change adaptation movement by supporting America Adapts!  Please consider supporting this podcast by donating through America Adapts fiscal sponsor, the Social Good Fund. All donations are now tax deductible! For more information on this podcast, visit the website at http://www.americaadapts.org and don't forget to subscribe to this podcast on Apple Podcasts.   Podcast Music produce by Richard Haitz Productions Write a review on Apple Podcasts ! America Adapts on Facebook!   Join the America Adapts Facebook Community Group. Check us out, we're also on YouTube! Executive Producer Dr. Jesse Keenan Subscribe to America Adapts on Apple Podcasts Doug can be contacted at americaadapts @ g mail . com

Presented by the ASC Research and Current Concepts Committee  Vicki Jo, MD, Chair & Amy Ly, MD, Vice Chair Dr. Heather Chen-Yost interviewed Dr. Abdol Aziz Ould Ismail, the winner of the Advances in Thyroid Cytology Award. This interview delves into the steps that led to this award-winning platform. Platform 6  Impact of a Comprehensive Quality Improvement Initiative for Reducing AUS Rates in Thyroid FNA Cytology: An Institutional Experience Abdol Aziz Ould Ismail, MD Dartmouth Hitchcock Medical Center Lebanon, New Hampshire Call for Abstracts for Platform and Poster Presentations DEADLINE TO SUBMIT ABSTRACTS - May 1, 2025  Click here to submit.

In today's podcast we were delighted to be joined by the presenters of the top scientific abstracts for the Annual Assembly of the American Academy of  Hospice and Palliative Medicine (AAHPM) and the Hospice and Palliative Medicine Nurses Association (HPNA).  Eric and I interviewed these presenters at the meeting on Thursday (before the pub crawl, thankfully).  On Saturday, they formally presented their abstracts during the plenary session, followed by a wonderful question and answer session with Hillary Lum doing a terrific job in the role of podcast host moderator. Our three guests were Marie Bakitas, who conducted a trial of tele/video palliative care for Black and White inpatients with serious illness hospitalized in the rural south; Yael Shenker, for a trial of patient-directed Prepare-for-your-care vs. facilitated Respecting Choices style advance care planning interventions; and, Na Ouyang, who studied the relationship between prognostic communication and prolonged grief among the parents of children who died from cancer.  From just the abstracts we had so many questions. We covered some of our questions on the podcast, others you can ponder on your own or in your journal clubs, including: Marie's tele/video palliative care intervention was tailored/refined with the help of a community advisory board. Does every institution need to get a community advisory board to tailor their rural tele-palliative care initiative (or geriatrics intervention) to the local communities served?  Who would/should be on that board? How to be sensitive to the risks of stereotyping based on recommendations from the few members of the board to the many heterogeneous patients served? Advance care planning has taken a beating. For the purposes of a thought exercise, no matter what you believe, let's assume that there are clear important benefits. Based on the results of Yael's study, should resources be allocated to resource intensive nurse facilitated sessions (Respecting Choices), which had significantly better engagement, or to low resource intensive patient-facing materials (Prepare), which had significantly less engagement but still plenty of engagement (e.g. 75% vs 61% advance directive completion)? One interpretation of Na's study is that clinicians can lean on the high levels of trust and high ratings of communication to engage with parents of children with cancer about prognosis.  Another interpretation is that clinicians avoided telling the parents prognosis in order to bolster their ratings of trust and communication quality.  Which is it? Bonus: Simon says he composed the song Sounds of Silence in a dark echoing bathroom about his concerns that people had stopped listening to each other in the 1960s (still resonates, right?).  Garfunkel says Simon was writing about Garfunklel's friend and college roomate Sandy, who was blind.  Who's got the right of it?   Enjoy! -Alex Smith   

“The biggest challenge for geophysicists? Learning machine learning's ‘new language' from the world of statistics.” Machine learning is transforming geoscience, and Gerard Schuster explains how. This conversation explores key ML applications in seismic interpretation, the role of convolutional neural networks in fault detection, and why hands-on labs are essential for mastering these techniques. With real-world examples and insights from his new book, Machine Learning Methods in Geoscience, this episode delivers practical knowledge for integrating ML into geophysics. KEY TAKEAWAYS > Why ML matters for geoscientists – The demand for ML skills is growing, and Jerry shares how this shift shapes education and careers. > CNNs in action – Convolutional neural networks are used to detect rock cracks in Saudi Arabia through drone imagery. > Transformers vs. traditional neural networks – Transformers process seismic data differently by capturing long-range dependencies, offering new advantages. NEXT STEP Explore Machine Learning Methods in Geoscience by Gerard Schuster, featuring hands-on MATLAB and Colab labs. Get the book and start applying ML techniques today! https://library.seg.org/doi/epdf/10.1190/1.9781560804048.fm TEXT A FRIEND These are great insights on how ML is actually being used in seismic work, not just theory. https://seg.org/podcasts/episode-249-machine-learning-methods-in-geoscience GUEST BIO Gerard Schuster has an M.S. (1982) and a Ph.D. (1984) from Columbia University and was a postdoctoral researcher there from 1984 to 1985. From 1985 to 2009, he was a professor of geophysics at the University of Utah and became a professor of geophysics at KAUST (2009–2021). He is currently a research professor at the University of Utah. He received several teaching and research awards while at the University of Utah. He was editor of GEOPHYSICS 2004–2005 and was awarded SEG's Virgil Kauffman Gold Medal in 2010 for his work in seismic interferometry. His previous books are Seismic Interferometry (2009, Cambridge Press) and Seismic Inversion (2017, SEG). LINKS * Buy the Print Book at https://seg.org/shop/product/?id=fe5a3cd3-77b2-ef11-b8e8-6045bda82e05 * Visit https://seg.org/podcasts/episode-249-machine-learning-methods-in-geoscience for the full guest bios and show notes. CALL FOR ABSTRACTS Technical Program Chairs Yingcai Zheng and Molly Turko invite you to submit your best work. This year, we're fostering deeper collaboration between SEG, AAPG, and SEPM. Focus on regional challenges and how integrated geoscience can unlock solutions. Submit short or expanded abstracts for oral and poster presentations. The Call for Abstracts is open and closes on 15 March at 5:00 PM CT. Don't miss this opportunity to share your research and connect with the broader geoscience community at https://www.imageevent.org/. SHOW CREDITS Andrew Geary at TreasureMint hosted, edited, and produced this episode. The SEG podcast team comprises Jennifer Cobb, Kathy Gamble, and Ally McGinnis. If you have episode ideas or feedback for the show or want to sponsor a future episode, email the show at podcast@seg.org.

"Reservoir characterization has evolved beyond oil and gas. It's now central to our clean energy future." In this episode, Andrew Geary speaks with Satinder Chopra and Heather Bedle, guest editors for December's The Leading Edge special section on reservoir characterization. They explore how this critical topic is transforming as geophysics expands its role in the global energy transition. From carbon storage to geothermal and hydrogen solutions, this episode highlights why reservoir characterization is at the heart of our clean energy future. KEY TAKEAWAYS > The Expanding Role of Reservoir Characterization: Learn how techniques traditionally used in oil and gas are now essential for carbon storage, geothermal projects, and hydrogen exploration. > Cutting-Edge Techniques in Action: Discover how advanced methods like full waveform inversion (FWI) and machine learning enhance our ability to map and monitor subsurface formations. > The Importance of Collaboration: Hear why integrating geophysics with geology, engineering, and other disciplines is crucial for solving modern subsurface challenges. NEXT STEP Explore the special section on reservoir characterization in December's The Leading Edge. Dive into the nine papers for actionable insights and real-world applications to guide your projects and decisions. https://library.seg.org/toc/leedff/43/12 TEXT A FRIEND Satinder and Heather share how AI and FWI are reshaping how we image the subsurface - inspiring information! https://seg.org/podcasts/episode-248-ai-fwi-and-the-future-of-subsurface-imaging/ GUEST BIOS Satinder Chopra is the founder and President of SamiGeo Consulting Ltd., located in Calgary. With 40 years of experience as a geophysicist, he specializes in processing, special processing, and the interactive interpretation of seismic data for reservoir characterization. His research interests focus on techniques for reservoir characterization. Dr. Heather Bedle is the Principal Investigator for Attribute-Assisted Seismic Processing and Interpretation (AASPI) and an Assistant Professor at the University of Oklahoma in the School of Geosciences. Her research and teaching focus on applying and developing advanced seismic interpretation. LINKS * Visit https://seg.org/podcasts/episode-248-ai-fwi-and-the-future-of-subsurface-imaging/ for links to the articles in The Leading Edge and the full guest bios. CALL FOR ABSTRACTS Technical Program Chairs Yingcai Zheng and Molly Turko invite you to submit your best work. This year, we're fostering deeper collaboration between SEG, AAPG, and SEPM. Focus on regional challenges and how integrated geoscience can unlock solutions. Submit short or expanded abstracts for oral and poster presentations. The Call for Abstracts is open and closes on 15 March at 5:00 PM CT. Don't miss this opportunity to share your research and connect with the broader geoscience community at https://www.imageevent.org/call-for-abstracts. SHOW CREDITS Andrew Geary at TreasureMint hosted, edited, and produced this episode. The SEG podcast team comprises Jennifer Cobb, Kathy Gamble, and Ally McGinnis. If you have episode ideas or feedback for the show or want to sponsor a future episode, email the show at podcast@seg.org.

News: Some US federal data is going offline, but you may be able to access duplicate copies on non-federal servers National Honor Society for Geospatial Technology applications open Penn State studies honey bee movements using QR codes Topic: Geography (and other) references we return to often. Events: GeoBusiness: 4-5 June, London RGS/IBG: 26-29 August. Birmingham, Abstracts due by March 7 GISPro: 6-9 Oct, Denver, CO, Abstracts due by May 5 Geography2050 (AGS): 20-21 November, NYC  

REPLAY: The Professional Artist with Echo Chernik Date: February 1st, 2025 Episode 37 - Join Echo as she interviews artist, nouveau-pirate, and philosopher Nigel Sade on his journey selling his art around the world. About Nigel Sade “Nigel Sade was born on a bright and sunny day nearly to some, and exactly to others, 40 years after D-day. Some consider this meaningful whilst the rest laugh at those people, but I digress. He was raised in hell ... or rather Ohio but I don't want to split hairs. In a smallish county called Portage. As a child he could be found drawing on any surface he could make a mark on, and with all the moving security deposits were more like donations. In School this A.D.H.D. Toth wannabe (but with hands) was considered a bit strange by his peers, ... a malady that never left him as it turned out. As a teenager he was a rebellious youth, A Technicolored street Freak, delving into every aspect of art, from Drawing to painting to Music to Religion to Science to Philosophy in general. Then there were the dark times ... the marriage! When his soul was crushed by evil and doubt. He Dreamt of being an artist but that was not a real job ... how could you feed a family with that pipe dream? However, In just 6 and a half long agonizing years it was over. On the Up side His torment was not without reward; He now has 2 lovely Spawn with which to explore life. Shortly after his divorce Nigel graduated college with a degree in Philosophy. So Armed with his freedom, his offspring, and an amazing ability to argue points that even he may not believe, he set out on the high seas of art! This was a joyous thing! There was much weirdness, art, travel, debauchery and Success. Stories were made and told, and now he Currently travel the amber waves of grain, questioning whatever reality he is presented with, chewing that up and spitting it out in the form of art. Then Nigel shows that art to the hapless masses in hopes that it moves them as much at it moved him to create it. Nigel's art in form is Symbolism (Much like Surrealism), represented in either a realism or Abstracts, and in function it explores basic ideas we hold, mostly it does so by exploring questions of Reality, Love, Thought and plain old strangeness. Nigel's belief is that art should spur conversation, not just match ones curtains. Now you may ask, "What does all this have to do with piracy?" Well, he was always a grungy, bandana wearin' freak. His family was and is highly Piratical What with their last name Rogers all the family businesses are Jolly Roger this and Jolly Roger that ... Not to mention their propensity for Rum. So with his families' nautical background and the new Pirate craze, the public proclaimed him a pirate, and a pirate he was. Yet, having always loved pirates, one can say Nigel got peanut butter in his chocolate!” Nigels's LinkTree: https://linktr.ee/NigelSade Echo Chernik Links: Website: https://www.EchoChernik.com Illustration: https://www.echo-x.com Facebook: https://www.facebook.com/echoxartist Instagram: https://www.instagram.com/echochernik Patreon: https://www.patreon.com/thexcaliberproject Kickstarter: https://www.kickstarter.com/profile/echox/created

In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovations, and Techniques (JVS-CIT). Editorials and Abstracts are read by members of the SVS Social Media Ambassadors. Guests: Dr. Gregory Magee, MD (@gregamagee) The past, present, and future of abdominal aortic aneurysm repair   Dr. Eric Pillado, MD (@drpillado) The need for standardizing care for pediatric and geriatric vascular trauma patients   Dr. Ben Li, MD (@ben_li123) Advanced chronic venous insufficiency and the role of the incompetent perforator vein: A 100-year quest for the right strategy Pediatric carotid body tumors: A case report and systematic review Early experience with baroreflex activation therapy from a vascular surgery perspective   Dr. Donald Baril, MD (@DonaldBaril) Early graft failure following lower extremity bypass   Dr. Michael Malinowski, MD Current challenges to vascular trauma training across levels and regions   Hosts: John Culhane (@JohnCulhaneMD) Nishi Vootukuru (@Nishi_Vootukuru)     Follow us @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

In episode 222 of America Adapts, I sit down with Dr. Carolyn Kousky, a leading expert in climate risk and insurance, to explore the transformative potential of 'Insurance for Good.' We discuss how climate change is not only intensifying risks like wildfires in California but also driving radical changes to insurance markets worldwide. Carolyn shares insights on how the industry can respond to these challenges by closing protection gaps, incentivizing resilience, and creating innovative solutions to build more climate-resilient communities. It's a timely and critical conversation at the intersection of insurance, wildfires, and the future of climate adaptation.   Battelle's ICR25 ICR25 brings together the world's brightest minds to solve the resilience challenge. This year's theme, “Partner, Accelerate, Launch,” highlights the critical need for innovative solutions to reach commercialization and impact resilience. Submit an abstract here:  Abstracts https://www.battelle.org/conferences/icr Register here: https://www.battelle.org/conferences/icr/technical-program-registration Check out the America Adapts Media Kit here! Subscribe to the America Adapts newsletter here. Donate to America Adapts Listen to America Adapts on your favorite app here!   Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Links in this episode: https://www.insuranceforgood.org/ Is California becoming Uninsurable? https://www.insuranceforgood.org/blog/is-california-becoming-uninsurable   Doug Parsons and Speaking Opportunities: If you are interested in having Doug speak at corporate and conference events, sharing his unique, expert perspective on adaptation in an entertaining and informative way, more information can be found here! Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Donate to America Adapts   Follow on Apple Podcasts Follow on Android Now on Spotify! List of Previous Guests on America Adapts Follow/listen to podcast on Apple Podcasts. Donate to America Adapts, we are now a tax deductible charitable organization!   Podcasts in the Classroom – Discussion guides now available for the latest episode of America Adapts. These guides can be used by educators at all levels. Check them out here! The 10 Best Sustainability Podcasts for Environmental Business Leadershttps://us.anteagroup.com/news-events/blog/10-best-sustainability-podcasts-environmental-business-leaders Join the climate change adaptation movement by supporting America Adapts!  Please consider supporting this podcast by donating through America Adapts fiscal sponsor, the Social Good Fund. All donations are now tax deductible! For more information on this podcast, visit the website at http://www.americaadapts.org and don't forget to subscribe to this podcast on Apple Podcasts.   Podcast Music produce by Richard Haitz Productions Write a review on Apple Podcasts ! America Adapts on Facebook!   Join the America Adapts Facebook Community Group. Check us out, we're also on YouTube! Executive Producer Dr. Jesse Keenan Subscribe to America Adapts on Apple Podcasts Doug can be contacted at americaadapts @ g mail . com

Art, S3x, and Sarcasm Episode 036: January 18, 2025 Nigel Sade and I take a break and have some fun. Art is more than a hobby or career — it's a lifestyle. About Nigel Sade “Nigel Sade was born on a bright and sunny day nearly to some, and exactly to others, 40 years after D-day. Some consider this meaningful whilst the rest laugh at those people, but I digress. He was raised in hell ... or rather Ohio but I don't want to split hairs. In a smallish county called Portage. As a child he could be found drawing on any surface he could make a mark on, and with all the moving security deposits were more like donations. In School this A.D.H.D. Toth wannabe (but with hands) was considered a bit strange by his peers, ... a malady that never left him as it turned out. As a teenager he was a rebellious youth, A Technicolored street Freak, delving into every aspect of art, from Drawing to painting to Music to Religion to Science to Philosophy in general. Then there were the dark times ... the marriage! When his soul was crushed by evil and doubt. He Dreamt of being an artist but that was not a real job ... how could you feed a family with that pipe dream? However, In just 6 and a half long agonizing years it was over. On the Up side His torment was not without reward; He now has 2 lovely Spawn with which to explore life. Shortly after his divorce Nigel graduated college with a degree in Philosophy. So Armed with his freedom, his offspring, and an amazing ability to argue points that even he may not believe, he set out on the high seas of art! This was a joyous thing! There was much weirdness, art, travel, debauchery and Success. Stories were made and told, and now he Currently travel the amber waves of grain, questioning whatever reality he is presented with, chewing that up and spitting it out in the form of art. Then Nigel shows that art to the hapless masses in hopes that it moves them as much at it moved him to create it. Nigel's art in form is Symbolism (Much like Surrealism), represented in either a realism or Abstracts, and in function it explores basic ideas we hold, mostly it does so by exploring questions of Reality, Love, Thought and plain old strangeness. Nigel's belief is that art should spur conversation, not just match ones curtains. Now you may ask, "What does all this have to do with piracy?" Well, he was always a grungy, bandana wearin' freak. His family was and is highly Piratical What with their last name Rogers all the family businesses are Jolly Roger this and Jolly Roger that ... Not to mention their propensity for Rum. So with his families' nautical background and the new Pirate craze, the public proclaimed him a pirate, and a pirate he was. Yet, having always loved pirates, one can say Nigel got peanut butter in his chocolate!” Nigels's LinkTree: https://linktr.ee/NigelSade Echo Chernik Links: Website: https://www.EchoChernik.com Illustration: https://www.echo-x.com Facebook: https://www.facebook.com/echoxartist Instagram: https://www.instagram.com/echochernik Patreon: https://www.patreon.com/thexcaliberproject Kickstarter: https://www.kickstarter.com/profile/echox/created

"Seismic attributes are not just colorful pictures; they're meaningful tools that can guide geoscientists to more accurate interpretations." In this episode, Andrew Geary sits down with Satinder Chopra and Kurt Marfurt, authors of Essentials of Seismic Attributes and Impedance Inversion, to discuss their comprehensive guide to understanding and applying seismic attributes in geophysics. They explore the power of attributes for interpreting seismic data, their practical applications, and common pitfalls to avoid. If you're ready to deepen your understanding of seismic attributes and their real-world impact, this conversation is packed with expert insights. KEY TAKEAWAYS > The Value of Attributes: Learn how seismic attributes unlock insights into stratigraphy, tectonics, and depositional systems beyond what amplitudes alone can reveal. > Practical Advice for Geoscientists: Discover tips on avoiding common pitfalls, from using preconditioned data to optimizing parameters and algorithms. > Integrated Interpretations: Explore how combining geology and seismic attributes leads to more accurate interpretations and successful outcomes. NEXT STEP Dive deeper into seismic attributes by reading the Front Matter for free at https://library.seg.org/doi/10.1190/1.9781560804062.fm. This book is a must-have resource for geoscientists looking to maximize the value of their data. TEXT A FRIEND Satinder and Kurt share workflows to get the most out of seismic data - worth listening to! https://seg.org/podcasts/episode-247-from-pitfalls-to-potential-making-the-most-of-seismic-attributes/ GUEST BIOS Satinder Chopra is the founder and President of SamiGeo Consulting Ltd., located in Calgary. With 40 years of experience as a geophysicist, he specializes in processing, special processing, and the interactive interpretation of seismic data for reservoir characterization. His research interests focus on techniques for reservoir characterization. Kurt J. Marfurt earned his Ph.D. in applied geophysics in 1978 from Columbia University's Henry Krumb School of Mines, New York. With the petroleum industry's movement to shale resource plays, Marfurt moved to the University of Oklahoma in 2007. There, he held the Frank and Henrietta Schultz professorship of geophysics at the ConocoPhillips School of Geology and Geophysics, where he is currently an Emeritus Professor. In recognition of his lifelong contributions to geoscience technology, Marfurt received the AAPG Robert Berg Award for Research in 2019 and SEG's Maurice Ewing Medal in 2023. LINKS * Buy the Print Book at https://seg.org/shop/product/?id=1ad0380a-5291-ef11-ac20-7c1e521bcb23 * Visit https://seg.org/podcasts/episode-247-from-pitfalls-to-potential-making-the-most-of-seismic-attributes/ for the full guest bios and show notes. CALL FOR ABSTRACTS Technical Program Chairs Yingcai Zheng and Molly Turko invite you to submit your best work. This year, we're fostering deeper collaboration between SEG, AAPG, and SEPM. Focus on regional challenges and how integrated geoscience can unlock solutions. Submit short or expanded abstracts for oral and poster presentations. The Call for Abstracts is open and closes on 15 March at 5:00 PM CT. Don't miss this opportunity to share your research and connect with the broader geoscience community at https://www.imageevent.org/call-for-abstracts. SHOW CREDITS Andrew Geary at TreasureMint hosted, edited, and produced this episode. The SEG podcast team comprises Jennifer Cobb, Kathy Gamble, and Ally McGinnis. If you have episode ideas or feedback for the show or want to sponsor a future episode, email the show at podcast@seg.org.

"Physics-based methods honor our understanding of the subsurface, while machine learning fills the gaps - but combining them is key." Andrew Geary chats with Mrinal Sen, a pioneer in seismic data analysis, about his Distinguished Instructor Short Course (DISC) and forthcoming book, Physics and Data Driven Seismic Data Analysis: A Narrative of Two Approaches. Mrinal shares how blending physics-based methods with machine learning unlocks new possibilities in seismic interpretation. Whether you're a student, geophysicist, or industry leader, this discussion is packed with insights into navigating the evolving landscape of seismic analysis. KEY TAKEAWAYS > The Power of Combining Approaches: Learn how integrating physics-driven and data-driven methods enhances seismic problem-solving. > Applications in Seismic Analysis: Discover real-world uses of machine learning, from denoising seismic data to improving full-waveform inversion. > A Practical Guide for Decision-Makers: Gain tools to decide when and how to leverage machine learning versus traditional physics-based techniques. NEXT STEP Ready to explore the future of seismic analysis? Enroll in Mrinal Sen's course to deepen your understanding and stay ahead at https://seg.org/education/courses/mrinal-sen-disc/. TEXT A FRIEND This episode explains when to choose physics vs. machine learning for seismic problems - so useful for decision-making! https://seg.org/podcasts/episode-246-combining-tradition-and-innovation-in-seismic-problem-solving/ GUEST BIO Mrinal K. Sen is a professor of Geophysics and holder of the Morgan Davis Centennial chair in Petroleum Geology at the Department of Earth and Planetary Sciences and the Institute for Geophysics at the University of Texas at Austin. During 2013 and 2014, Mrinal was the director of the National Geophysical Research Institute, Hyderabad, India. He received his M.Sc degree from IIT Dhanbad and PhD from the University of Hawaii at Manoa, USA. LINKS * Visit https://seg.org/podcasts/episode-246-combining-tradition-and-innovation-in-seismic-problem-solving/ for Mrinal's full biography and the complete show notes. JOIN THE SEG COMMUNITY Studying geosciences? The Society of Exploration Geophysicists is your key to success. * Boost your career: Access mentorship, scholarships, and discounted conferences. * Expand your knowledge: Explore the SEG Library – a treasure trove of articles, books, and papers on the latest advancements. * Connect globally: Network with geoscientists worldwide, discuss and collaborate on projects. * Enhance your skills: Benefit from various continuing education programs. * Unlock your potential: Join SEG and elevate your geoscience journey. Learn more about membership benefits at https://seg.org/membership/. CALL FOR ABSTRACTS Technical Program Chairs Yingcai Zheng and Molly Turko invite you to submit your best work. This year, we're fostering deeper collaboration between SEG, AAPG, and SEPM. Focus on regional challenges and how integrated geoscience can unlock solutions. Submit short or expanded abstracts for oral and poster presentations. The Call for Abstracts is open and closes on 15 March at 5:00 PM CT. Don't miss this opportunity to share your research and connect with the broader geoscience community at https://www.imageevent.org/call-for-abstracts. SHOW CREDITS Andrew Geary at TreasureMint hosted, edited, and produced this episode. The SEG podcast team comprises Jennifer Cobb, Kathy Gamble, and Ally McGinnis. If you have episode ideas or feedback for the show or want to sponsor a future episode, email the show at podcast@seg.org.

PCICS Podcast Episode 123: Top QI Abstracts 2024: Part 1 of 2 by The Podcast for Pediatric Cardiac Critical Care

In episode 221 of America Adapts, we're hosting some of the world's leading adaptation experts (and previous podcast guests) to make climate predictions for  2025! From the growing impacts of wildfires reshaping communities, extreme heat, adaptation technology, to the potential massive shifts in climate policy under a new presidential administration, this year promises to be a turning point. Join us as we explore the trends, innovations, and strategies that will define climate adaptation in the year to come. You won't want to miss what these experts have to say about the future of climate adaptation! Experts in this Episode: Dr. Jesse Keenan – Favrot II Associate Professor of Sustainable Real Estate and Urban Planning, Director, Center on Climate Change and Urbanism at Tulane University Dr. AR Siders – Director of the Gerard J. Mangone Climate Change Science and Policy Hub at the University of Delaware Shaun Martin – Vice President, Adaptation and Resilience, World Wildlife Fund Dr. Shalini Vajjhala – Executive Director of PRE Collective Mark Nevitt – Associate Professor of Law at the Emory University School of Law Dr. Carolyn Kousky – Founder Insurance for Good Beth Gibbons – Director of the Resiliency Office Washtenaw County, Michigan Dr. Ladd Keith – Associate professor in the School of Landscape Architecture and Planning, University of Arizona Emilie Mazzacurati – Co-Founder of Tailwind Battelle's ICR25 ICR25 brings together the world's brightest minds to solve the resilience challenge. This year's theme, “Partner, Accelerate, Launch,” highlights the critical need for innovative solutions to reach commercialization and impact resilience. Submit an abstract here:  Abstracts https://www.battelle.org/conferences/icr Register here: https://www.battelle.org/conferences/icr/technical-program-registration Check out the America Adapts Media Kit here! Subscribe to the America Adapts newsletter here. Donate to America Adapts Listen to America Adapts on your favorite app here!   Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Links in this episode: US National Adaptation and Resilience Planning Strategy 2025 https://unfccc.int/documents/645358 https://www.worldwildlife.org/pages/climate-adaptation-and-resilience-program   Doug Parsons and Speaking Opportunities: If you are interested in having Doug speak at corporate and conference events, sharing his unique, expert perspective on adaptation in an entertaining and informative way, more information can be found here! Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Donate to America Adapts   Follow on Apple Podcasts Follow on Android Now on Spotify! List of Previous Guests on America Adapts Follow/listen to podcast on Apple Podcasts. Donate to America Adapts, we are now a tax deductible charitable organization! Federal Reserve Bank of San Francisco Strategies to Address Climate Change Risk in Low- and Moderate-income Communities - Volume 14, Issue 1 https://www.frbsf.org/community-development/publications/community-development-investment-review/2019/october/strategies-to-address-climate-change-low-moderate-income-communities/   Podcasts in the Classroom – Discussion guides now available for the latest episode of America Adapts. These guides can be used by educators at all levels. Check them out here! The 10 Best Sustainability Podcasts for Environmental Business Leadershttps://us.anteagroup.com/news-events/blog/10-best-sustainability-podcasts-environmental-business-leaders Join the climate change adaptation movement by supporting America Adapts!  Please consider supporting this podcast by donating through America Adapts fiscal sponsor, the Social Good Fund. All donations are now tax deductible! For more information on this podcast, visit the website at http://www.americaadapts.org and don't forget to subscribe to this podcast on Apple Podcasts.   Podcast Music produce by Richard Haitz Productions Write a review on Apple Podcasts ! America Adapts on Facebook!   Join the America Adapts Facebook Community Group. Check us out, we're also on YouTube! Executive Producer Dr. Jesse Keenan Subscribe to America Adapts on Apple Podcasts Doug can be contacted at americaadapts @ g mail . com

"Fiber optics can thrive in the harshest environments, proving robust for oil, gas, and carbon capture projects." This episode dives into the cutting-edge world of fiber optics with Joël Le Calvez, guest editor for November 2024's The Leading Edge. Fiber optics, a technology ubiquitous in daily life, is revolutionizing geophysics, offering real-time, cost-effective, and highly precise data collection capabilities. Joël breaks down six groundbreaking papers showcasing how fiber optics transform oil and gas, carbon capture, and even seafloor imaging. KEY TAKEAWAYS > Revolutionary Applications: Fiber optics enables continuous, distributed sensing over large areas, reducing costs and increasing operational efficiency for seismic surveys, leak detection, and more. > Cutting-Edge Innovations: The special section highlights advancements in distributed acoustic sensing (DAS) for seismic profiling, carbon storage monitoring, and real-time event detection. > Bridging Disciplines: Fiber optics has the potential to break down silos in geoscience, fostering interdisciplinary collaboration through shared data acquisition methods. NEXT STEP Explore the November 2024 issue of The Leading Edge to dive deeper into these transformative studies. Read the special section at https://library.seg.org/toc/leedff/43/11 and consider how fiber optics can innovate your projects. TEXT A FRIEND Ever wonder how real-time sensing can monitor CO2 storage? This podcast brilliantly explains it. Listen here: https://seg.org/podcasts/episode-245-fiber-optics-in-action-the-future-of-geophysical-sensing. GUEST BIO Joël Le Calvez graduated with a B. Sc. in Physics, an M. Sc. in Geosciences, a pre-doctoral degree in Geodynamics, and a Ph. D. in Geology. For two decades, Joel spent time in the field and the office helping decide on drilling locations, acquiring and processing microseismic data, and leading teams of geologists, geophysicists, and engineers in North America about hydraulic fracturing campaigns. 2014 Joel became the Global Head of the Geophysics Domain and added the North America Well Integrity and Production Logging businesses to his portfolio. In January 2022, Joel took the Reservoir Performance Optical Fiber program manager position before adding the Production Services portfolio a semester later. He coordinates the effort associated with cable and interrogator manufacturing, research and development directions, and business-focused answer products for all domains relying on fiber optic to acquire data. LINKS * Visit https://seg.org/podcasts/episode-245-fiber-optics-in-action-the-future-of-geophysical-sensing for the complete show notes and links to read this special section. CALL FOR ABSTRACTS OPENS 15 JANUARY Technical Program Chairs Yingcai Zheng and Molly Turko invite you to submit your best work. This year, we're fostering deeper collaboration between SEG, AAPG, and SEPM. Focus on regional challenges and how integrated geoscience can unlock solutions. Submit short or expanded abstracts for oral and poster presentations. The Call for Abstracts opens on 15 January and closes on 15 March at 5:00 PM CT. Don't miss this opportunity to share your research and connect with the broader geoscience community. SHOW CREDITS Andrew Geary at TreasureMint hosted, edited, and produced this episode. The SEG podcast team comprises Jennifer Cobb, Kathy Gamble, and Ally McGinnis. If you have episode ideas or feedback for the show or want to sponsor a future episode, email the show at podcast@seg.org.

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the ESSENCE trial, the Phase 3 trial demonstrating that semaglutide regresses fibrosis levels in some MASH patients.  The conversation begins with each panelist sharing a word or short phrase they felt best captured their feelings about TLM2024. Next, panelists review the meeting's most consequential paper, the ESSENCE Trial. Naim starts by describing ESSENCE, a Phase 3 trial with semaglutide demonstrating significant levels of fibrosis regression in non-cirrhotic MASH patients. Jörn adds the hopeful note that NITs performed as well as or better than biopsy in this trial, which he hopes will speed the transition in diagnostic approaches and tools. Jeff and Mike agree that from the patient's perspective, ESSENCE will be seen as a milestone in MASH therapy: the proof that a second drug can succeed in MASH. As the conversation ends, Roger notes that approval of a second agent for a particular disease often leads to dramatic growth in overall drug treatment by changing the pivotal question from whether to treat with a drug to which choice to prescribe. 

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation considers how the anticipated approval of a second MASH drug without biopsy might affect clinical trials and discusses two recent publications on patient genotyping and patient clusters. The conversation starts with Roger asking the group whether the presence of two approved MASH medications that do not require biopsy will make recruiting clinical trials that require them more challenging. The group doubts this will not add a significant new challenge to already-challenging trial recruitment. Naim comments that while this is a concern, it is already factored into trial schedules and that, given the number of patients available for trial, this should be highly manageable. Michelle discusses the importance of risk stratification in overall trial enrollment and this issue. Jeff and Mike agree that while this is a concern, it is part of a broader concern about the use of biopsy and should not in itself be a primary focus in terms of trial design at this point in time. Naim introduces two other topics he considers worthy of consideration: the impact of synergy between resmetirom and GLP-1 agonists and the importance of different genetic polymorphisms in predicting the impact of drugs on specific patients. On synergy, he comments that MAESTRO-NASH data suggests that the presence of a GLP-1 does not affect the impact of resmetirom on fibrosis level. On the second point, he notes that several papers looked at major genotypes like PNPLA3 and HD17N13 and specifically cites a late-breaker from Arun Sanyal indicating that g-allele status may impact MASH independent of weight or insulin. Michelle mentions a recent paper in Nature identifying distinct clusters of patients based on how their SLDs progress over time, with a two-cluster solution indicating patients with concomitant diabetes and obesity vs. those without these two concomitant diseases. Roger shares a key point from each paper on treatment in the US. Data in the PNPLA3 paper might suggest that the course of disease in Hispanics, who have high levels of g-allele abnormalities, might be different from other ethnic groups with far lower abnormality rates. He also notes that the faster disease progression in the non-metabolic cluster highlights the importance of learning more about Lean MASH and how to treat it, since faster progression of disease suggests later diagnosis and higher morbidity, mortality and treatment costs levels.

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews the late-breaker presentation on efimosermin, a q4w FGF-21 agent and the "FDA Corner" session. Jörn begins the discussion by highlighting a paper from the later breaker session on efimosfermin alfa, an FGF-21 agent dosed q4w. He notes that after only six doses (24 weeks), efimosfermin alfa demonstrated significant increases in fibrosis regression and lowering NAS score. To Jörn, this result, coupled with others on efruxifermin and pegozafermin, suggest that FGF-21s are likely to play a significant role in MASH therapy once approved. After Roger and Mike note their enthusiasm about the drug class and this study, Jörn mentions a study with 96-week efruxifermin that data demonstrates prolonged efficacy. As he points out, this matters because while studies of an earlier FGF-21 candidate suggested that antibodies might develop in FGF-21 therapy, that does not appear to be an issue here. Mike asks the group why they feel placebo performs so well in clinical trials. Jörn suggests that working with a compassionate clinical care team in dealing with the patient leads to better performance on diet and exercise and, as a result, increased placebo response to what we might find in general community practice.Michelle praises the FDA Corner session, particularly the agency's transparency and willingness to engage industry and academia in finding paths to move away from biopsy. She also notes some of the practical challenges inherent of moving away from biopsy using data from earlier trials with an outmoded histology reader setup. She is optimistic about the scientific community coming together to address these issues. Jeff praises the agency for an "amazing" session. 

Did you miss IDWeek this year and trying to catch up on the hot topics? Or was there just too many good sessions and you want to catch up on the ones you missed? Let the Breakpoints Hostesses help you out! In the first of two IDWeek 2024 recap episodes, join Drs. Erin McCreary, Julie Ann Justo, Jeannette Bouchard, and Megan Klatt as they cover top late breaking abstracts and stewardship data that you won't want to miss! References: BALANCE Trial: Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. 10.1056/NEJMoa2404991 White et al. Antibiotic stewardship targets in the outpatient setting. 10.1016/j.ajic.2019.01.027 Wattengel et al. Outpatient antimicrobial stewardship: Optimizing patient care via pharmacist led microbiology review. 10.1016/j.ajic.2019.07.018 Augostini et al. An evaluation of antimicrobial prophylaxis for transrectal prostate biopsies: A potential stewardship target. 10.1016/j.ajic.2024.05.012 Cotter et al. Antibiotic use and outcomes among children hospitalized with suspected pneumonia. 10.1002/jhm.13002

In episode 220 of America Adapts, we're diving into a new project from Tailwind: The Adaptation & Resilience Innovation Playbook. In this episode, I chatted with Katie MacDonald, co-founder of Tailwind, a pioneering firm dedicated to driving innovation in climate adaptation. Katie and her team at Tailwind are at the forefront of helping companies tackle some of the most pressing climate hazards—think wildfires, heat waves, and more. And now, they've taken it a step further with their latest project: a comprehensive playbook that maps out the booming adaptation market, which is projected to hit $2 trillion by 2030. We unpack the playbook's core insights, from the critical role of governments driving over half of global demand for adaptation solutions to the untapped potential of corporations as the "sleeping giants" of resilience. We'll explore how startups are rising to the challenge, despite funding gaps, and why engaging communities and addressing health and social system blind spots are essential for success. Katie also shares actionable recommendations for policymakers, entrepreneurs, and everyday citizens on how to seize opportunities in this emerging market. Battelle's ICR25 ICR25 brings together the world's brightest minds to solve the resilience challenge. This year's theme, “Partner, Accelerate, Launch,” highlights the critical need for innovative solutions to reach commercialization and impact resilience. Submit an abstract here:  Abstracts https://www.battelle.org/conferences/icr Register here: https://www.battelle.org/conferences/icr/technical-program-registration   Check out the America Adapts Media Kit here! Subscribe to the America Adapts newsletter here. Donate to America Adapts Listen to America Adapts on your favorite app here!  Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Links in this episode: https://www.tailwindclimate.com/ The Adaptation & Resilience Innovation Playbook   Doug Parsons and Speaking Opportunities: If you are interested in having Doug speak at corporate and conference events, sharing his unique, expert perspective on adaptation in an entertaining and informative way, more information can be found here! Facebook, Linkedin and Twitter: https://www.facebook.com/americaadapts/ @usaadapts https://www.linkedin.com/in/doug-parsons-america-adapts/ Donate to America Adapts   Follow on Apple Podcasts Follow on Android Now on Spotify! List of Previous Guests on America Adapts Follow/listen to podcast on Apple Podcasts. Donate to America Adapts, we are now a tax deductible charitable organization! Federal Reserve Bank of San Francisco Strategies to Address Climate Change Risk in Low- and Moderate-income Communities - Volume 14, Issue 1 https://www.frbsf.org/community-development/publications/community-development-investment-review/2019/october/strategies-to-address-climate-change-low-moderate-income-communities/   Podcasts in the Classroom – Discussion guides now available for the latest episode of America Adapts. These guides can be used by educators at all levels. Check them out here! The 10 Best Sustainability Podcasts for Environmental Business Leadershttps://us.anteagroup.com/news-events/blog/10-best-sustainability-podcasts-environmental-business-leaders Join the climate change adaptation movement by supporting America Adapts!  Please consider supporting this podcast by donating through America Adapts fiscal sponsor, the Social Good Fund. All donations are now tax deductible! For more information on this podcast, visit the website at http://www.americaadapts.org and don't forget to subscribe to this podcast on Apple Podcasts.   Podcast Music produce by Richard Haitz Productions Write a review on Apple Podcasts ! America Adapts on Facebook!   Join the America Adapts Facebook Community Group. Check us out, we're also on YouTube! Executive Producer Dr. Jesse Keenan Subscribe to America Adapts on Apple Podcasts Doug can be contacted at americaadapts @ g mail . com

In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovates, and Techniques (JVS-CIT). Editorials and Abstracts are read by members of the SVS Social Media Ambassadors.   Readers: Nick Schaper (@schapernj) Nabeeha Khan (@Nabeeha_Khan_)   Hosts: John Culhane (@JohnCulhaneMD) Nishi Vootukuru (@Nishi_Vootukuru)   Reference Articles: The Gore Iliac Branch Endoprosthesis as an alternate aortic main body: Promising results in select patients A classic article that has never been read in English     Follow us @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

Researcher Jindong Wang and Associate Professor Steven Euijong Whang explore the NeurIPS 2024 work ERBench. ERBench leverages relational databases to create LLM benchmarks that can verify model rationale via keywords in addition to checking answer correctness. Read the paperGet datasets and codes

In this Pregnancy Meeting edition of the SMFM Podcast, Dr. Shannon Son welcomes Dr. Allison  Bryant to discuss everything you need to know about posters and abstracts at the 2025 Pregnancy Meeting. From the equity-focused review process to the impressive lineup of over 1,100 poster  presentations and groundbreaking oral sessions, this year's meeting promises to showcase the  best in maternal-fetal medicine research. Discover how sustainability initiatives are shaping the format of the meeting, what's new for poster presenters, and why this year's program is a must-attend event for anyone in the field. Plus, get key tips to make the most of your experience with the SMFM mobile app and learn about important deadlines for registration and planning. Mark your calendar for January 27 to February 1, 2025, at the Gaylord Rockies Resort in Denver,  Colorado. Be sure to subscribe to the SMFM Podcast Series for more updates and visit  smfm.org/2025 to register today   Click here for the full episode transcript. 

Pranjal Chitale discusses the '24 NeurIPS work CVQA. Spanning 31 languages and the cultures of 30 countries, this VQA benchmark was created with native speakers and cultural experts to evaluate model performance across diverse linguistic and cultural contexts.Read the paperGet the dataset

Can existing algorithms designed for simple reinforcement learning problems be used to solve more complex RL problems? Researcher Dylan Foster discusses the modular approach he and his coauthors explored in their 2024 NeurIPS paper on RL under latent dynamics.Read the paper

Next-token prediction trains a language model on all tokens in a sequence. VP Weizhu Chen discusses his team's 2024 NeurIPS paper on how distinguishing between useful and “noisy” tokens in pretraining can improve token efficiency and model performance.Read the paperGet the code

ImmunoCAST visited the 2024 American College of Allergy, Asthma, and Immunology meeting and collected some of the most interesting and important research papers which were unveiled during the conference. Whether you're an allergist or a primary care clinician, tune in to hear some of the most exciting research and insights that are coming out of the field of allergy, including the role of climate change on latex allergy, the role of allergic rhinitis and food allergy on mental health, and much more. Episode resources and references available at https://www.thermofisher.com/phadia/us/en/resources/immunocast/s2e12.html?cid=0ct_3pc_05032024_9SGOV4

ACR 2024 starts tomorrow; here are a few previews of Abstracts to be presented. Along with my recommendations of sessions you don't want to miss.  

The efficient simulation of molecules has the potential to change how the world understands biological systems and designs new drugs and biomaterials. Tong Wang discusses AI2BMD, an AI-based system designed to simulate large biomolecules with speed and accuracy.Read the paperGet the code

In this episode, Microsoft senior principal researchers Chris Hawblitzel and Jay Lorch join host Amber Tingle to discuss “Verus: A Practical Foundation for Systems Verification,” which received the Distinguished Artifact Award at this year's Symposium on Operating Systems Principles, or SOSP. In their research, Hawblitzel, Lorch, and their coauthors leverage advances in programming languages and formal verification with two aims. The first aim is to help make software verification more accessible for systems developers so they can demonstrate their code will behave as intended. The second aim is to provide the research community with sound groundwork to tackle the application of formal verification to large, complex systems.Read the paper

In their 2024 SOSP paper, researchers explore a common—though often undertested—software system issue: retry bugs. Research manager Shan Lu and PhD candidate Bogdan Stoica share how they're combining traditional program analysis and LLMs to address the challenge.Read the paper

In this episode, we spotlight editorials and abstracts from the Journal of Vascular Surgery Cases, Innovates, and Techniques (JVS-CIT). Editorials and Abstracts are read by members of the SVS Social Media Ambassadors.   Readers: David Ebertz (@EbertzDavid) Kori Snider (@KoriSnider) Nabeeha Khan (@Nabeeha_Khan_)   Hosts: John Culhane (@Johnculhanemd) Nishi Vootukuru (@Nishi_Vootukuru)   Reference Articles: Sutureless endovascular bypass technique in long femoropopliteal occlusions Technical feasibility and device stability of the Gore Excluder iliac branch endoprosthesis as abdominal aortic bifurcated device Retrograde aortic dissection during thoracic endovascular aortic repair: How to prevent and treat Retroperitoneal approach for ilio-superior mesenteric artery bypass: Technique and case series Randomized controlled trials in emergency settings: Taking a HEADSTART on acute type A aortic dissection trials Presentation and management of true aneurysms of the pancreaticoduodenal arcade with concomitant celiac artery stenosis using the endovascular approach Regarding “Aortic rupture during STABILISE (stent-assisted balloon-induced intimal disruption and relamination in aortic dissection repair) technique” Temporary mesenteric venous shunting for portal vein reconstruction: A novel technical adjunct   Follow us @audiblebleeding   Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.